Research and Markets has announced the addition of the "Helicobacter pylori Infections - Pipeline Review, H2 2016" report to their offering.
Helicobacter pylori Infections pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes.
Helicobacter pylori Infections - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Helicobacter pylori Infections Helicobacter pylorus (H. pylori) is a bacterium present in the stomach. Infection with H. pylori usually causes no symptoms, though H. pylori can cause many digestive problems including ulcers, and, sometimes, stomach cancer. H. pylori infection is transmitted by the consumption of food or water contaminated with fecal matter. H. pylorus leads to changes in the stomach and duodenum, leading to the release of certain enzymes and toxins, which may directly or indirectly injure the cells of the stomach or duodenum. Stomach or duodenal ulcers may also develop.
The most common symptoms include pain or discomfort (usually in the upper abdomen), bloating, feeling full after eating a small amount of food, lack of appetite, nausea or vomiting, dark or tar-colored stools and ulcers that bleed and cause a low blood count and fatigue. The molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/9m586q/helicobacter
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005688/en/Business Wire
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.